Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib, Trametinib in patients with Melanoma.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.